Back to the Virtual Exhibit Hall
| ||||
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical Company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs for the treatment of cancer and other diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. https://www.karyopharm.com Product Information Fact Sheet
Gregg Stewart Hematology/Oncology Specialist 724-316-4448
| ||||
|
|
| ||
